RADAR PANC UK
Research type
Research Study
Full title
Recurrent diseAse Detection After Resection of PANCreatic adenocarcinoma using a standardized surveillance strategy (RADAR PANC UK). The UK arm of an international trial.
IRAS ID
318048
Contact name
Keith John Roberts
Contact email
Sponsor organisation
The University of Birmingham
Clinicaltrials.gov Identifier
Duration of Study in the UK
2 years, 9 months, 1 days
Research summary
Despite curative surgery for patients with pancreatic cancer (PDAC), almost all patients will experience recurrence around the same area or at another site in their body within 2 years. Currently, there is limited evidence of effective treatments for patients who have local recurrence only and in those with distant recurrence, chemotherapy improves survival by 3-4 months. Because of this, there is a reluctance to follow up these patients. In most European countries, there is no standardised follow-up following surgery for PDAC. However, more effective treatments are emerging focused on local and distant recurrence which is leading to interest in the early diagnosis of PDAC recurrence. Therefore, to identify patients who would benefit from these experimental treatments, a standardised follow-up of patients is necessary.
The main aim of this study would be to assess whether a standardised surveillance would impact on the overall survival and quality of life in patients who have had curative surgery for PDAC compared to the current non-standardised practice.
Patients would be randomly assigned to undergo either standardised surveillance or non-standardised follow-up. This standardised surveillance would include routine CT scans of their chest and abdomen every 3 months, a specific tumour marker and experimental biomarkers for the first 2 years after surgery. The main outcomes would be a comparison of the overall survival and quality of life of these patients. Other outcomes would include how well patients complied with a standardised surveillance programme, patterns of recurrence and the effect of standardised surveillance on patients being eligible for additional treatment for their recurrence and the tolerance of that treatment.
REC name
West Midlands - South Birmingham Research Ethics Committee
REC reference
24/WM/0132
Date of REC Opinion
9 Jul 2024
REC opinion
Further Information Favourable Opinion